TY  - JOUR
AU  - San José-Enériz, Edurne
AU  - Agirre, Xabier
AU  - Rabal, Obdulia
AU  - Vilas-Zornoza, Amaia
AU  - Sanchez-Arias, Juan A
AU  - Miranda, Estibaliz
AU  - Ugarte, Ana
AU  - Roa, Sergio
AU  - Paiva, Bruno
AU  - Estella-Hermoso de Mendoza, Ander
AU  - Alvarez, Rosa María
AU  - Casares, Noelia
AU  - Segura, Victor
AU  - Martín-Subero, José I
AU  - Ogi, François-Xavier
AU  - Soule, Pierre
AU  - Santiveri, Clara M
AU  - Campos-Olivas, Ramón
AU  - Castellano, Giancarlo
AU  - García Fernández de Barrena, Maite
AU  - Rodríguez-Madoz, Juan Roberto
AU  - García-Barchino, Maria José
AU  - Lasarte, Juan Jose
AU  - Avila, Matias A
AU  - Martinez-Climent, Jose Angel
AU  - Oyarzabal, Julen
AU  - Prosper, Felipe
PY  - 2017
DO  - 10.1038/ncomms15424
SN  - 2041-1723
UR  - http://hdl.handle.net/20.500.12105/6883
AB  - The indisputable role of epigenetics in cancer and the fact that epigenetic alterations can be reversed have favoured development of epigenetic drugs. In this study, we design and synthesize potent novel, selective and reversible chemical probes that...
LA  - eng
PB  - Nature Publishing Group
KW  - Animals
KW  - Antineoplastic Agents
KW  - Apoptosis
KW  - Cell Line, Tumor
KW  - Cell Proliferation
KW  - Crystallography, X-Ray
KW  - DNA Modification Methylases
KW  - Dose-Response Relationship, Drug
KW  - Drug Evaluation, Preclinical
KW  - Enzyme Inhibitors
KW  - Epigenesis, Genetic
KW  - Female
KW  - Hematologic Neoplasms
KW  - Histocompatibility Antigens
KW  - Histone-Lysine N-Methyltransferase
KW  - Humans
KW  - Interferons
KW  - Mice
KW  - Mice, Inbred BALB C
KW  - Microsomes, Liver
KW  - Molecular Docking Simulation
KW  - Survival Analysis
KW  - Treatment Outcome
KW  - Xenograft Model Antitumor Assays
KW  - Drug Design
TI  - Discovery of first-in-class reversible dual small molecule inhibitors against G9a and DNMTs in hematological malignancies
TY  - journal article
ER  -